Interestingly, inhibition of TBK1 in mouse liver by the TBK1 inhibitor BX795 reduces p62 inclusions, production of ROS, and liver fibrosis during NASH. Here, TBK1 is linked to metabolic dysfunction-associated steatohepatitis.